Many international studies have shown that the detection of serum CA125, HE4, and gynecological ultrasound has great clinical value in malignant risk assessment of ovarian neoplasms (34); the levels of CAl25 and HE4 in patients with malignant tumors are higher than in patients with benign or borderline tumors (21, 35–38). Here, WFDC2 is linked to ovarian neoplasm.